Homburger advised ADC Therapeutics , a commercial-stage biotechnology company with headquarters in Switzerland, on its USD 60 m private placement of common shares and pre-funded warrants. TCGX led the operation, with further participation from Redmile Group and
Tags :Daniel Häusermann
Homburger advised Santhera in connection with its CHF 20 m royalty monetization and convertible bond financing. The deal encompassed an USD 13 m royalty monetization financing with R-Bridge, an affiliate of Singapore-based healthcare-focused investment firm CBC Group.
Homburger advised ADC Therapeutics on its USD 100 m Private Placement of Common Shares and Pre-Funded Warrants. The context Headquartered in Switzerland and listed on the NYSE under the ticker ADCT, ADC Therapeutics is a commercial-stage
Homburger advised Temenos on the completion of the sale of its fund administration software business to Montagu Private Equity. The company Headquartered in Geneva, Temenos serves the global banking market with enterprise software solutions. Its
Homburger advised the selling shareholders of Samaplast, a privately held Swiss company, on the sale of 100% of the company to a group of investors led by Philipp Looser. The company Samaplast is a specialist in
The Kellenberger family has significantly reduced its ownership in Calida Holding through two key transactions: a public buy-back offer and a direct share repurchase. Homburger served as legal advisor to the Kellenberger family, guiding them
Homburger is acting as the legal advisor to Liberty Global and Sunrise Communications AG in relation to the spin-off and dual listing of Sunrise on the SIX Swiss Exchange and NASDAQ. The transaction, announced on
Homburger advised Meyer Burger Technology on the completion of a reverse split (on July 1, 2024) of its shares in the ratio 750:1, which had been approved by its annual general meeting of shareholders held on June 25, 2024. The
Homburger advised Santhera Pharmaceuticals on its entrance into a royalty monetization financing totaling up to USD 38 m with R-Bridge, an affiliate of CBC Group, amongst Asia’s largest healthcare-focused investment firms. Santhera is monetizing 75% of
Homburger advised ADC Therapeutics, a commercial-stage biotechnology company producing antibody drug conjugates (ADCs) for cancer patients, on its 13.4 m of common shares, and, to certain investors who so choose in lieu of common shares, pre-funded
